uniQure N.V. (QURE)
After hours:
uniQure N.V.
Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 480
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew Craig Kapusta | CEO & Executive Director | 1.16M | N/A | 1972 |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 566.36k | N/A | 1973 |
| Mr. Pierre Caloz | Chief Operating Officer | 951.1k | N/A | 1972 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | N/A | N/A | N/A |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | N/A | N/A | N/A |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer | N/A | N/A | 1962 |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | N/A | N/A | N/A |
| Ms. Carla Poulson | Interim Chief People and Culture Officer | N/A | N/A | N/A |
| Ms. Maria E. Cantor | Chief Corporate Affairs Officer | 491.12k | N/A | 1968 |
| Dr. Amin Abujoub Ph.D. | Chief Quality Officer | N/A | N/A | N/A |
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Corporate Governance
uniQure N.V.’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 1; Compensation: 5.
